G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

22 Feb 2023 10:00:17 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

13 Feb 2023 06:00:38 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2023 16:46:01 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference

11 Jan 2023 07:00:47 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

09 Jan 2023 06:30:31 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023

04 Jan 2023 06:30:12 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference

03 Jan 2023 14:00:27 By Nasdaq GlobeNewswire

Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment

07 Dec 2022 18:04:19 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2022 23:41:26 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference

23 Nov 2022 10:30:26 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Closing of Offering of Common Stock

22 Nov 2022 16:01:04 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Pricing of Offering of Common Stock

17 Nov 2022 20:12:26 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Proposed Public Offering of Common Stock

17 Nov 2022 16:01:05 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights

02 Nov 2022 06:30:33 By Nasdaq GlobeNewswire

Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)

02 Nov 2022 06:28:23 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2022 17:40:30 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

26 Oct 2022 09:26:34 By Nasdaq GlobeNewswire

G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022

19 Oct 2022 12:30:57 By Nasdaq GlobeNewswire

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)

10 Oct 2022 06:30:06 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2022 17:00:53 By Nasdaq GlobeNewswire